← Eichor
Condition: Locally Advanced Or Metastatic Malignant Solid Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Locally Advanced Or Metastatic Malignant Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT05991583A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Phase 1/Phase 2 · 2 location(s) · RemeGen Co., Ltd. · NCT05205850A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic
Phase 1/Phase 2 · 31 location(s) · RemeGen Co., Ltd. · NCT06016062Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06418061Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or G
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT04511039Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Phase 2 · 7 location(s) · Centre Leon Berard · NCT02029001Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study of TAK-505 in Adults With Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Takeda · NCT07436728Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04879121Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Astellas Pharma Global Development, Inc. · NCT07287995GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT06292208Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05059678A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
Phase 1/Phase 2 · 39 location(s) · RemeGen Co., Ltd. · NCT07105215A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
Phase 1/Phase 2 · 18 location(s) · RemeGen Co., Ltd. · NCT06038396A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancre
Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT05705492The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750DBC-664 in Adult Patients With Solid Tumors
Phase 1 · 3 location(s) · Duboce Biopharmaceuticals, Inc. · NCT07705035Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.